ArticleAntimicrobial agents and chemotherapy2016
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Article
- Optimizing antifungal dosing for invasiveFrontiers in pharmacology · 2025Article
- Advancing cryptococcal treatment: The role of nanoparticles in mitigating antifungal resistance.Current research in microbial sciences · 2025Review
- Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosisAntimicrobial agents and chemotherapy · 2023Article
- Methods for Antifungal Susceptibility Testing of theJournal of fungi (Basel, Switzerland) · 2023Review
- Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosisbioRxiv : the preprint server for biology · 2023Article
- Clinical and pathological characterization of Central Nervous System cryptococcosis in an experimental mouse model of stereotaxic intracerebral infection.PLoS neglected tropical diseases · 2023Article
- The Role of Isavuconazonium Sulphate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility.Open forum infectious diseases · 2022Article
- Successful Treatment of Cryptococcal Meningitis and Cryptococcoma with Isavuconazole in a Patient Living with HIV.Journal of fungi (Basel, Switzerland) · 2021Article
- Isavuconazole-Animal Data and Clinical Data.Journal of fungi (Basel, Switzerland) · 2020Review
- Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods forAntimicrobial agents and chemotherapy · 2020Article
- Extrapolating Antifungal Animal Data to Humans - Is it reliable?Current fungal infection reports · 2020Article
- Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT.Journal of neurology · 2020Article
- Isavuconazole Therapy of Disseminated and EncephalicMediterranean journal of hematology and infectious diseases · 2020Article
- Isavuconazole Diffusion in Infected Human Brain.Antimicrobial agents and chemotherapy · 2019Article
- Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.Antimicrobial agents and chemotherapy · 2019Article
- Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.Antimicrobial agents and chemotherapy · 2019Article
- Central Nervous System Cryptococcal Infections in Non-HIV Infected Patients.Journal of fungi (Basel, Switzerland) · 2019Review
- Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.European journal of drug metabolism and pharmacokinetics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the efficacy of isavuconazole against cryptococcal meningitis. Treatment with either oral isavuconazole (120 mg/kg and 240 mg/kg twice a day [BID]) or fluconazole as the positive control significantly improved survival in mice infected intracranially with either Cryptococcus neoformans USC1597 or H99 and significantly reduced brain fungal burdens for both isolates. Concentrations of isavuconazole in plasma and brain tissue also demonstrated that the greatest improvements in survival and fungal burden were associated with elevated exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.